Tysabri Side Effects Not as Serious as Projected
by Kevin Rippey on Nov.23, 2009, under Nanotech Company Info, Pharmaceuticals, Safety Concerns
Biogen and Elan’s (NASDAQ: ELN) multiple sclerosis drug Tysabri has been a subject of serious concern as a rare brain infection PML has been a known side effect of the drug. However, more recent reports have shown that the frequency as well as the severity of the side effect is not as grave as originally thought. In fact, initial estimates of the frequency of PML as a side effect was 1/1000. However, data collected over the past 4 years has shown that the frequency is closer to 1/2500.
Full Story: Here
November 23rd, 2009 on 7:21 pm
Your synopsis of the Tysabri/PML issues was very well done. I have followed many Internet links since my daughter has been on Tysabri for her MS for several years in order to stay as up to date as possible with the assessments of the risks and with the new attempts to ammelieorate those risks. You have not, I believe, sugar coated anything while your factual information has provided hope that risks will be dealt with in the future. Thank you for such a cogent piece.
November 23rd, 2009 on 9:23 pm
A great deal of thanks for your comment Deb. My best wishes for you and your daughter as she continues her fight.
-Kev